APR is owned by Relief Therapeutics (SIX:RLF, www.relieftherapeutics.com), a Swiss, commercial-stage, biopharmaceutical company focused on the identification, development, and commercialization of novel, patent-protected products intended for the treatment of rare and ultra-rare diseases.Running global Business Development & Licensing initiatives, spanning from In-licensing, due diligence, financial and commercial evaluations, business cases, out-licensing of marketed products and assets in pipeline, negotiations with partners, royalty streams optimization, representation in international fairs and B2B events.

www.go-nucleo.com is the online workplace for the life sciences industry connecting people, products and services. Register for free.

Ethypharm -incl. Martindale UK and Altan Spain - is an European specialty pharmaceutical company focused on CNS (pain, addiction, depression) and Hospital Injectables (emergency and intensive care).Driving sales and Business Development activities, managing 40+ Alliance and Distribution partners and NGOs with responsibility for P&L, Commercial Policies, and Budget Planning.Driving Strategy across key countries, growth creation, and integration of portfolios.

Driven Sales and Business Development activities with responsibility for P&L, led in/out-licensing and asset acquisitions, scouting distributors and partners. incl. market data and analysis for business cases preparation. Setting up affiliates structures in key countries. Teamwork & project managed new product introductions and geo extensions.

Orfe (www.orfe.ru) is the largest Western Distributor and 4PL of Pharmaceuticals and Medical Devices in Russia.Led Business development in Europe by identifying suitable clients in Italy, Germany, Austria, Switzerland, UK, France, Spain, and in Russia by pitching local incumbents. Revised Strategy, marketing plans, business models, communication & PR.

Pharmaxis is an Australian pharmaceutical research company and a global leader in drug development for inflammation and fibrotic diseases. In Russia Pharmaxis has successfully launched the product Bronchitol (specialty pharma: cystic fibrosis).Coordinated the local team of MSLs, arranged coach and selling skills and sales trainings, revised KPIs and targeting of pulmonologists, participated in round-table and KOLs value-based seminars. Revised local Distribution and Supply chain networks, incl. financial flows, compliance framework with Western standards.

Mallinckrodt is an Irish-American manufacturer of specialty pharmaceuticals. In Russia we launched Synacthen Depot, a specialty product used in Neurology, Multiples sclerosis (MS), Infantile spasms. Mallinckrodt has approximately 5k employees worldwide and the company’s fiscal 2015 revenue totalled $3.7 billion.Managed Russian P&L, local systems and compliance, budget planning. Hired and managed staff, mentored and coached them. Selected distributors, set policies, bona fides & financials, vendors – incl. PV and local SOPs. Led local Market Access activities and developed Marketing & Sales plan nationwide Russia.